We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Q&A Guidance Provides Clarity on Adaptive Licensing Pilot Program
EMA Q&A Guidance Provides Clarity on Adaptive Licensing Pilot Program
The European Medicines Agency wants to help manufacturers take advantage of its adaptive licensing pilot program, which aims to speed patient access to new treatments via a process that authorizes products for use by targeted populations in stages.